Sirona Biochem Corp V.SBM

Here is the link

[biorun]

From the german boards.

This looks to be a 10 bagger if they can get it through as he is suggesting. This would entirely change the perception of the company and value of the scientific platform all around. Sirona has at least the first $35-40 million pf revenue tax free due to the loss carry forward from previous years. 

Come on Sirona, lets get this party started. Go fricken go!!!

Sirona Biochem: Major Deal with Top 10 Pharmaceutical Giant Imminent? 

https://twitter.com/PRCexposure/status/14895861302156

[biorun]

Well that one didn't work when i clicked it here is the link to the main page https://www.prc-partners.com/post/sirona-biochem-major-deal-with-top-10-pharmaceutical-giant-imminent

[biorun]

well, I give up. the article was there but some reason the web browser won't let me through. I will try to copy paste some how if I can find the link again. sorry folks. 

[navajojoe]

This post has been removed in accordance with Community Policy

[biorun]

He was suggesting 32M annual on licensing royalties. That alone brings in excess of $1.50 per share minimum, plus animal health as the home run. You need to do some math my friend.

[navajojoe]

This post has been removed in accordance with Community Policy

[biorun]

You obviously didn't go to finance school. That's ok. EPS multiplier of 10.8x to 17x (for emerging biotech) = $1.51 to $2.38 Valuation multiples are widely known to be higher if the broader science platform is demonstrated to have further reaching implications.

[BurningMoney5]

I agree with the simple maths, however, it will only come to fruition if Howard finally make a deal, a big deal!!! Let's all hope!!!

[biorun]

That I do agree with. Proof in the pudding. BTW - someone just messaged me saying Barclays is buying right now. That is a new player I believe.

[navajojoe]

This post has been removed in accordance with Community Policy

[biorun]

Overhead cost on the licencing deal is approx $2.5M, which is essentially the current/ongoing corporate overhead. These types of licencing revenues have very little future variable costs associated with it. The typical licensing scenario is different from the R&F agreement where the ingredients raw are supplied. Near pure profit scenario. Stop talking please. Moron.

[navajojoe]

This post has been removed in accordance with Community Policy

[biorun]

Great, so this back and forth is about interfering with you retirement plans? I think you want a steady and predictable outcome here, but you are not going to get it. Maybe there is no deal? This is a junior biotech and IF they land the great deals then this becomes a roller coaster of buying and selling and postulation about growth possibilities. If they land the kind of deal that PRC is

[navajojoe]

This post has been removed in accordance with Community Policy

[biorun]

So you think. You will likely not be able to retire and cash out. You will have to wait for a buyout. Sorry.